Tag Archives: Maryland

Second West Nile case reported in Boston

Health officials in Boston have reported that a 75-year-old man has become the second city resident to test positive for West Nile Virus this year. Read More »

Filed in News | Tagged | Comments Off

Emergent BioSolutions among 2010 tech awards finalists

ROCKVILLE, Md. Read More »

Filed in News, Vaccine Development | Tagged , | Comments Off

Emergent BioSolutions’ CEO recognized as outstanding international business leader

ROCKVILLE, Md. Read More »

Filed in News, Vaccine Development | Tagged , | Comments Off

Cyto Pulse, Karolinska Institutet get clinical trial approval

Cyto Pulse Sciences announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet and the Swedish Institute for Infectious Disease Control. Read More »

Filed in News, Vaccine Development | Tagged , , | Comments Off

Novavax, Rovi end flu vaccine development plan

TEL AVIV, Israel Read More »

Filed in News, Vaccine Development | Tagged , | Comments Off

More than 3 million doses of BioThrax delivered to HHS

Emergent BioSolutions Inc. that it has successfully completed the fourth-quarter 2006 deliveries of more than 3 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Department of Health and Human Services. Read More »

Filed in National Institutes of Health , News | Tagged , | Comments Off

Emergent BioSolutions gets $24 million to develop anthrax monoclonal antibody

ROCKVILLE, Md. Read More »

Filed in News, Vaccine Development | Tagged , | Comments Off

HHS says proposal to provide anthrax vaccine ‘technically acceptable’

Emergent BioSolutions Inc. announced that the Department of Health and Human Services has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable. Read More »

Filed in News, Vaccine Development | Tagged , | Comments Off

Emergent BioSolutions signs $29.7 million contract to develop anthrax vaccine

U.S. to purchase 14.5 million more doses of BioThrax

U.S. includes BioThrax, Anthrax Immune Globulin in PREP Act

DHS approves BioThrax as a product for homeland security

NIAID gives 2 grants for development of anthrax immune globulin therapeutic

Emergent BioSolutions says CFO to join board of MdBio Foundation

Emergent BioSolutions submits proposal to develop new anthrax vaccine

NIAID awards 2 grants to Emergent BioSolutions for vaccine development

Joint venture aims to develop advanced tuberculosis vaccine

Former DHHS secretary joins board of directors of Emergent BioSolutions

Government extends deadline for plans to develop anthrax rPA vaccine

Emergent BioSolutions announces start of anthrax treatment trial

Emergent BioSolutions acquires monoclonal anthrax product candidate

FDA approves a high dose flu influenza vaccine intended for seniors

Emergent BioSolutions’ chief financial officer named SmartCFO of the Year

Md. governor praises Emergent BioSolutions

Emergent BioSolutions acquires manufacturing facility from MdBio

Emergent BioSolutions’ typhoid vaccine achieves positive results in clinical study